Although some ongoing early-phase clinical trials are including patients with BRAF non-V600 mutations, their capacity to provide robust and specific analysis for novel agents targeting BRAF non-V600 mutations in CRC is yet to be determined. Here, BRAF is linked to colorectal carcinoma.